계명대학교 의학도서관 Repository

Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)

Metadata Downloads
Affiliated Author(s)
김진희
Alternative Author(s)
Kim, Jin Hee
Journal Title
Breast
ISSN
1532-3080
Issued Date
2019
Keyword
Breast cancerNeoadjuvant chemotherapyTumor bed boostRadiotherapy
Abstract
Purpose:
This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT).

Materials and methods:
We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed.

Results:
In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p ¼ 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p ¼ 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS.
Department
Dept. of Radiation Oncology (방사선종양학)
Publisher
School of Medicine (의과대학)
Citation
Won Kyung Cho et al. (2019). Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16). Breast, 45, 43–47. doi: 10.1016/j.breast.2019.02.010
Type
Article
ISSN
1532-3080
DOI
10.1016/j.breast.2019.02.010
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41951
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.